The Clinical Response Evaluation of the Medtronic Endeavor CR ABT-578 Eluting Coronary Stent System in De Novo Native Coronary Artery Lesions.

Trial Profile

The Clinical Response Evaluation of the Medtronic Endeavor CR ABT-578 Eluting Coronary Stent System in De Novo Native Coronary Artery Lesions.

Completed
Phase of Trial: Phase I/II

Latest Information Update: 11 Nov 2011

At a glance

  • Drugs Zotarolimus (Primary)
  • Indications Coronary artery disease; Coronary artery restenosis
  • Focus Adverse reactions; Registrational; Therapeutic Use
  • Acronyms RESOLUTE-First in Human
  • Most Recent Events

    • 19 Oct 2011 Actual end date (Oct 2011) added as reported by ClinicalTrials.gov.
    • 23 Sep 2010 Four-year results were presented at the 2010 Transcatheter Cardiovascular Therapeutics (TCT) conference, according to a Medtronic media release.
    • 21 Sep 2010 3-year long-term results were presented at the 22nd Annual Scientific Symposium on Transcatheter Cardiovascular Therapeutics.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top